Suchergebnisse
Suchergebnisse:
Maidique, Modesto A. "Biodel, Inc." Harvard Business School Case 681-004, July 1980. (Revised October 1980 ...
12. Mai 2014 · Patent number: 9060927. Abstract: Injectable insulin formulations with improved stability and rapid onset of action are described herein. The formulations may be for subcutaneous, intradermal or intramuscular administration. In the preferred embodiment, the formulations are administered via subcutaneous injection.
4. Nov. 2016 · Albireo Ltd. and Biodel Inc. completed their share exchange transaction to create a combined organization that will develop novel bile acid modulators to treat orphan pediatric liver diseases. The new entity, called Albireo Pharma Inc., commences trading on the Nasdaq Capital Market on Nov. 4 under the symbol ALBO.
Biodel Ag, Inc., a regenerative agriculture company, closed its Series A financing round led by Pangaea Ventures Ltd, a renowned venture capital firm with a focus on advanced materials and clean technology. The funding will support Biodel AG's commitment to accelerating commercialization of novel solutions aimed at enhancing soil health, optimizing water utilization, improving nutrient ...
04.12.2014 - DANBURY, CT--(Marketwired - December 04, 2014) - Biodel Inc. (NASDAQ: BIOD) today announced that the company has initiated enrollment of normal human subjects in a Phase 1 clinical ...
Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes that may be safer, more effective and more convenient for patients. We develop our product candidates by applying our proprietary formulation technologies to existing drugs in order to improve their therapeutic profiles. For further information regarding ...
11. Aug. 2014 · (Reuters) - Biodel Inc said its experimental insulin formulation was found more effective than current therapies in controlling glucose after two meals, in a mid-stage trial. Shares of the ...
